bluebird bio, Inc.

Events

Genetix (est. 1992) become bluebird bio

September 2010

First transfusion-dependent β-thalassemia patient treated

May 2014

First sickle cell disease patient treated

October 2014

First multiple myeloma patient treated

February 2016

β-thalassemia drug receives PRIME status

September 2016

ADL treatment designated as Breakthrough Therapy

May 2018

EU marketing authorization for Zynteglo®

June 2019